Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the ...
Compounded by the equally sudden banning of the weight loss drug, phen-fen (phentermine-fenfluramine ... there remained no new promising pharmaceutical agents addressing obesity.
Weight loss drugs catapulted many into a new wellness era ... of new drugs looking to enter the market. Between August 2021 and August 2023, the prevalence of obesity among adults was 40 ...
Data from the National Health and Nutrition Examination study show that between 2021-2023 ... And what about the new weight loss drugs? The Kaiser Family Foundation reported in its spring ...
these findings and the new drug approval offer hope for potential relief beyond CPAP and surgery. Before Eli Lilly's weight loss drug was approved by the Food and Drug Administration for ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback